Epidemiological surveys indicate that the incidence of inflammatory bowel disease (IBD) is
increasing rapidly with the continuous growth of the economy. A large number of studies …

Hosting millions of microorganisms, the digestive tract is the primary and most important part
of bacterial colonization. On one side, in cases of opportunistic invasion, the abundant …

Ulcerative colitis (UC) is driven by disruptions in host–microbiota homoeostasis, but current
treatments exclusively target host inflammatory pathways. To understand how host …

Inflammatory bowel disease (IBD) is a chronic immune-mediated disease affecting the
gastrointestinal tract. IBD consists of 2 subtypes: ulcerative colitis and Crohn disease. IBD is …

Background: Gut microbiota, which plays a crucial role in inflammatory bowel diseases
(IBD), might have therapeutic benefits for ulcerative colitis or Crohn's disease. Targeting gut …

Inflammatory bowel diseases (IBDs) develop as a result of complex interactions among
genes, innate immunity and environmental factors, which are related to the gut microbiota …

Inflammatory bowel diseases (IBDs), represented by Crohn disease and ulcerative colitis,
are associated with major morbidity in Western countries and with increasing incidence in …

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a
chronic and relapsing inflammatory disorder of the intestine. Although its incidence is …

Interleukin (IL)-18 was originally discovered as a factor that enhanced IFN-γ production from
anti-CD3-stimulated Th1 cells, especially in the presence of IL-12. Upon stimulation with Ag …

Gut microbiota metabolites may be important for host health, yet few studies investigate the
correlation between human gut microbiome and production of fecal metabolites and their …